Portal Innovations Report Highlights Capital Efficiency and Growth Potential in Emerging U.S. Biotech Hubs
Portal Innovations has announced the release of Biotech’s Next Frontier: Emerging Hubs Built for Efficiency and Outsized Returns, a new industry analysis examining financing trends, clinical development timelines and company exit outcomes across the U.S. biotechnology sector over the past decade.
Developed by Portal Innovations’ venture team, the report evaluates data from more than 11,000 life sciences companies and nearly 30,000 financing deals between 2015 and 2025. It compares established biotechnology centers in California and Massachusetts with emerging life sciences ecosystems across other regions of the United States.
The analysis challenges conventional assumptions about what makes a biotechnology ecosystem successful. Although established hubs continue to benefit from extensive venture capital networks, specialized talent pools, research institutions and mature commercialization infrastructure, the findings suggest that companies operating outside these traditional centers may demonstrate advantages in capital efficiency, clinical development speed, founder ownership retention and resilience during changing investment conditions.
According to the report, emerging biotech ecosystems are becoming increasingly important contributors to U.S. life sciences innovation. Their performance suggests that companies may be able to advance scientific discoveries and reach important development milestones without relying on the same levels of private financing typically associated with established biotechnology centers.
The findings also highlight the importance of strengthening connections between regional ecosystems, investors, research institutions and industry partners to help promising companies progress from early-stage discovery toward commercial development.
Emerging Biotech Ecosystems Demonstrate Greater Capital Efficiency
One of the report’s central findings concerns the relationship between investment and financial returns. According to Portal Innovations, companies operating in emerging biotechnology ecosystems generated higher median returns on invested capital at exit than companies based in established hubs.
Capital efficiency is an important consideration in biotechnology because developing new medicines, diagnostics and other life sciences technologies can require substantial financial resources over extended periods. Companies often need to fund scientific research, validate technologies, conduct preclinical studies, complete clinical trials and establish regulatory and manufacturing capabilities before reaching commercialization.
These activities can require multiple rounds of financing, making the amount of capital needed to achieve development milestones a significant factor in determining a company’s long-term financial prospects.
The report’s findings suggest that emerging ecosystems may provide an environment in which biotechnology companies can deploy capital more efficiently and potentially generate stronger returns for investors at exit.
This does not necessarily mean that every company outside established hubs will outperform its counterparts in California or Massachusetts. Biotechnology investment outcomes depend on numerous factors, including the scientific quality of a program, clinical results, intellectual property protection, management expertise, market demand and the availability of financing.
However, the reported difference in median returns challenges the assumption that locating a company in a traditional biotechnology center is inherently associated with superior investment performance.
For investors evaluating new opportunities, the findings suggest that regional location should be considered alongside company-specific factors such as technology differentiation, development strategy, financing requirements and commercial potential.
Faster Clinical Milestones With Less Private Capital
The report also identifies differences in clinical development timelines and financing requirements between emerging ecosystems and established biotechnology hubs.
According to Portal Innovations, startups in emerging ecosystems reached their first clinical trial milestones faster on average while requiring less private capital.
Clinical development represents one of the most financially demanding stages of biotechnology innovation. Moving a potential therapeutic product from laboratory research into human studies involves scientific validation, preclinical testing, regulatory preparation, clinical operations and the coordination of specialized service providers.
The ability to reach an initial clinical milestone efficiently can be important for early-stage companies. Demonstrating that a product candidate is ready for clinical evaluation may help a company attract additional investors, establish pharmaceutical partnerships or secure further funding to advance its development program.
For companies with limited financial resources, reaching such milestones with less private capital may also reduce the pressure to raise large financing rounds before generating meaningful development data.
The report’s findings raise the possibility that emerging ecosystems can support more focused operating models, allowing startups to direct resources toward critical research and development activities.
Potential contributors include access to academic research institutions, regional innovation programs, specialized service providers and partnerships that help companies obtain the capabilities they need without building every function internally.
Nevertheless, the relationship between funding levels and development speed must be considered in context. Different biotechnology programs have different scientific requirements, clinical endpoints, regulatory pathways and levels of complexity. A company developing a relatively straightforward diagnostic technology may face different development demands from one advancing a novel treatment for a complex disease.
The report’s findings provide a comparative perspective on startup performance, but they do not establish that geography alone causes faster development or lower capital requirements.
Emerging Ecosystems Show Greater Resilience After the COVID-Era Investment Period
Another significant finding concerns the ability of biotechnology companies to attract financing as market conditions changed.
Portal Innovations compared the COVID-era period, defined in the analysis as 2018–2021, with the post-COVID period from 2022 through 2025. During this transition, companies in emerging ecosystems recorded a 23.3% increase in capital raised, while companies in established hubs experienced a 14.7% decline.
The figures suggest that emerging ecosystems demonstrated greater resilience in the face of changing biotechnology investment conditions.
The biotechnology sector experienced considerable shifts in investor sentiment and financing availability during and after the COVID-19 pandemic. The pandemic drew substantial attention to vaccines, diagnostics, therapeutics and other life sciences technologies, while subsequent market conditions changed the funding environment for many companies.
For biotechnology startups, fluctuations in financing availability can have important operational consequences. Companies may need to adjust hiring plans, delay research programs, extend existing cash resources or seek alternative sources of capital when investors become more selective.
A comparatively resilient financing environment can help startups maintain development momentum and continue advancing promising technologies during periods of market uncertainty.
The increase in capital raised by companies in emerging ecosystems may also reflect a broader distribution of investment opportunities across the United States. As investors evaluate companies beyond traditional biotechnology centers, regional ecosystems may benefit from additional attention and access to financing.
However, aggregate funding trends do not necessarily indicate that every emerging market experienced growth or that every established hub faced declining investment. Financing outcomes can vary significantly by company, therapeutic area, stage of development and transaction size.
Even so, the reported contrast offers investors and regional economic development organizations a reason to reassess how biotechnology investment opportunities are distributed across the country.
Founder Ownership Retention Offers Another Advantage
The analysis also found that companies in emerging biotechnology ecosystems experienced less dilution, allowing founders to retain a greater share of ownership.
Equity dilution occurs when a company issues additional shares to investors, reducing the percentage ownership held by existing shareholders unless they participate proportionately in the financing. In biotechnology, dilution is a common feature of company development because many startups need several rounds of investment to support research, clinical development and commercialization.
Although raising external capital can provide the resources required to advance a program, repeated fundraising can significantly reduce founders’ ownership stakes over time.
Lower dilution may allow founders and early shareholders in emerging ecosystems to preserve more ownership as companies grow. This can influence the distribution of financial returns if a company is acquired, completes another type of exit or reaches a successful commercial stage.
Founder ownership retention may also affect the long-term incentives of company leaders and early employees. Preserving a meaningful ownership stake can help align their interests with the company’s future performance.
For investors, however, dilution must be evaluated alongside the amount of capital raised, the company’s financing needs, its valuation and the progress achieved with each financing round. A company that raises less capital may experience less dilution, but it must still secure sufficient resources to complete critical development activities.
The report’s findings therefore highlight founder ownership as an additional measure of ecosystem performance rather than an independent indicator of company quality or investment returns.
Public Funding Plays an Important Role in Early-Stage Innovation
Portal Innovations also examined the contribution of government-backed, non-dilutive funding programs to biotechnology development.
The analysis found that companies outside traditional biotechnology hubs accounted for nearly 70% of the startups receiving the Small Business Innovation Research and Small Business Technology Transfer grants included in the study.
The SBIR and STTR programs provide funding to eligible small businesses to support research and development activities. Unlike conventional equity financing, these grants generally do not require companies to surrender ownership in exchange for funding.
Such funding can be particularly valuable for early-stage biotechnology companies, which may need resources to validate a scientific concept, develop a prototype, generate preliminary data or establish the technical foundation for a larger research program.
Access to non-dilutive funding can help startups advance early development activities before raising substantial amounts of private capital. It may also provide an opportunity to demonstrate technical progress and strengthen the case for subsequent investment.
The report’s finding that nearly 70% of the analyzed grant recipients were located outside traditional hubs highlights the importance of public funding in supporting a geographically diverse innovation landscape.
For companies in emerging ecosystems, government research programs can complement regional venture capital, university partnerships and other sources of financial support. These funding mechanisms may help companies develop technologies that would otherwise struggle to attract sufficient private investment during their earliest stages.
The results also suggest that policymakers seeking to expand biotechnology innovation should consider how public research funding can support companies across different regions, rather than concentrating attention exclusively on established centers.
Established Hubs Retain Important Structural Advantages
Despite the reported strengths of emerging ecosystems, the analysis does not suggest that established biotechnology centers have lost their importance.
California and Massachusetts continue to offer substantial advantages for life sciences companies, including experienced biotechnology executives, venture capital firms, research universities, hospitals, clinical research networks and established pharmaceutical industry relationships.
These resources can be especially important for companies developing complex technologies that require specialized expertise, large clinical programs or extensive commercialization capabilities.
Established ecosystems may also provide greater access to experienced investors who understand the financial and regulatory demands of biotechnology development. Dense professional networks can facilitate partnerships, recruitment, licensing agreements and acquisition opportunities.
Emerging ecosystems may face different challenges, particularly when companies need large follow-on financing rounds, access to specialized laboratory infrastructure or relationships with pharmaceutical companies capable of supporting late-stage development.
The report therefore presents the two types of ecosystems as having different strengths rather than treating them as interchangeable.
Established hubs offer mature infrastructure and extensive networks, while emerging ecosystems may provide opportunities for more disciplined capital deployment, lower dilution and greater financing resilience.
For the broader biotechnology industry, the challenge is to combine these advantages and improve the connections that allow companies to access the resources they need as they mature.
Building Stronger Connections Across Regional Ecosystems
The report concludes that the future of U.S. biotechnology innovation depends on strengthening collaboration across regional ecosystems rather than simply reproducing the established hub model in additional locations.
Building a successful biotechnology company requires more than scientific expertise or access to initial funding. Startups also need specialized facilities, experienced management, clinical development capabilities, regulatory guidance, manufacturing partners and access to follow-on capital.
Companies in emerging ecosystems may develop promising technologies efficiently but encounter difficulties when they need larger investments or more extensive commercialization support.
Improving access to these resources could help high-potential businesses continue developing their technologies without being forced to relocate or depend exclusively on the financing networks of traditional hubs.
Potential areas for improvement include stronger connections between regional startups and established venture capital firms, expanded access to specialized infrastructure, greater collaboration with pharmaceutical and biotechnology companies, and more effective pathways from academic research to commercial development.
Investors and ecosystem builders could also use a broader set of performance measures when assessing regional biotechnology markets. In addition to total venture capital raised, factors such as capital efficiency, clinical development timelines, founder ownership retention and access to non-dilutive funding may provide a more complete picture of an ecosystem’s strengths.
Such an approach could help identify investment opportunities that might otherwise receive less attention because they are located outside established biotechnology centers.
Portal Innovations Releases Analysis of a Changing Biotechnology Landscape
Through Biotech’s Next Frontier: Emerging Hubs Built for Efficiency and Outsized Returns, Portal Innovations presents a data-driven assessment of how regional biotechnology ecosystems have performed across financing, development and exit activity.
Drawing on more than 11,000 life sciences companies and nearly 30,000 financing deals from 2015 through 2025, the analysis highlights differences between traditional hubs and emerging regions in several areas of company performance.
Its key findings include higher median returns on invested capital at exit for companies in emerging ecosystems, faster average progress toward first clinical milestones with less private capital, a 23.3% increase in capital raised during the post-COVID period, lower founder dilution and a substantial contribution from companies receiving SBIR/STTR grants.
Together, these findings challenge the idea that biotechnology success depends primarily on proximity to established venture capital centers. They instead point to the importance of capital discipline, access to appropriate resources, supportive funding mechanisms and connections across the broader innovation network.
For investors, founders, policymakers and regional development organizations, the analysis offers a framework for evaluating where biotechnology companies are being built and how they can be supported through different stages of growth.
The report’s broader message is that expanding the geographic reach of biotechnology innovation does not require abandoning established hubs. Instead, connecting mature centers with emerging ecosystems could create more pathways for scientific discoveries to advance toward clinical and commercial milestones.
About Portal Innovations
Portal Innovations is a venture development platform that provides early-stage capital, specialized lab space, and strategic resources to science-driven companies. With headquarters in Chicago and an expanding international footprint, Portal’s Crafted Capital model bridges the gap between scientific discovery and commercialization, helping entrepreneurs transform cutting-edge research into successful businesses.